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ABSTRACT 
Pedersen, N.C., Johnson, L., Birch, D., and Theilen, G.H. 1986. 
Possible immunoenhancement of persistent viremia by feline leukemia virus 
envelope glycoprotein vaccines in challenge-exposure situations where whole 
inactivated virus vaccines were protective. Vet. Immunol. Inmlunopathol., ii: 
123-148. 
Kittens immunized with purified native FeLV-gp70 or -gp85 envelope 
proteins developed ELISA, but not virus neutralizing, antibodies in their 
serum to both whole FeLV and FeLV-gp70. Kittens vaccinated with envelope 
proteins and infected with feline sarcoma virus (FeSV) developed smaller 
tumors than nonvaccinates, but a greater incidence of persistent 
retroviremia. Similarly, FeLV-gp70 and -gp85 vaccinated kittens were more 
apt to become persistently retroviremic following virulent FeLV challenge 
exposure than nonvaccinates. 
Kittens vaccinated with inactivated whole FeLV developed smaller tumors 
after FeSV inoculation and had a lower incidence of persistent retroviremia 
than nonvaccinates. The protective effect of inactivated whole FeLV 
vaccine against persistent retroviremia was also seen with FeLV challenge- 
exposed cats. Protection afforded by inactivated whole FeLV vaccine was 
not associated with virus neutralizing antibodies, although ELISA 
antibodies to both whole FeLV and FeLV-gp70 were induced by vaccination. 
INTRCDUCTION 
Feline leukemia virus (FeL93 infection is one of the most devastating 
diseases of domestic cats. As many as 1 to 6% of free-roaming household 
cats and 30% of cats in some catteries and multiple cat homes are chroni- 
cally infected (Hardy, 1981; Pedersen et al., 1980). Feline leukemia 
virus infection induces a myriad of different diseases, and is directly or 
indirectly responsible for about one-third of all chronic illness in 
domestic cats in some parts of the United States (Pedersen et al., 1980). 
Prevention of FeLV infection is, therefore, a high priority for veterinary 
researchers. Similar to other viral infections, vaccination appears to be 
the most logical approach to prevention. The fact that a majority of older 
cats in nature recover from viremia after infection indicates that cats can 
mount an active irmm~ne response to FeLV under appropriate oonditions 
(Hardy, 1981; Pedersen et al., 1977, 1978). 
0165-2427/86/$03.50 © 1986 Elsevier Science Publishers B.V. 
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Over the last decade there have been numerous reports dealing with FeLV 
vaccination. These included the use of crude vaccines made up of soluble 
products of virus infected cells (Lewis et al., 1981; Mathes et al., 1981), 
whole live or dead FeLV infected tumor cells (Grant et al., 1980, Jarrett 
et al., 1975, 1976; Olsen et al., 1976), inactivated whole FeLV (Hoover et 
al., 1977; Olsen et al., 1977; Pedersen et al., 1978; Yohn et al., 1976), 
live virus (Hardy, 1981; Pedersen et al., 1978), and viral envelope subunit 
proteins (Salerno et al., 1978). The efficacy of these various vaccines 
was tested by measuring for the acquisition of virus neutralizing anti- 
bodies (Salerno et al., 1978), by challenging cats with fibrosarcoma 
virus preparations (Grant et al., 1980; Olsen et al., 1977; Yohn et al., 
1976) or virulent FeLV (Hardy, 1981; Hoover et al., 1977; Jarrett et al., 
1975, 1976), or by contact exposure with chronically infected cats 
(Pedersen et al., 1978). Some of these vaccines have protected cats against 
infection with virulent virus, while others have not. 
The present emphasis of most FeLV vaccine research is on genetically 
engineered viral subunit proteins, either in the form of bacterial or yeast 
expressed products or synthetic oligopeptides. Among the various virus 
structural proteins, the 70,000 dalton envelope glycoprotein (FeLV-gp70) 
has been thought to be responsible for evoking protective in%~]nity in cats 
(Hardy, 1981; Salerno et al., 1978). In mice, marine leukemia virus gp71 
covalently linked to its 15,000 dalton transenvelope anchoring protein 
(gp71-pl5E or gp85) has been shown to he even more immunogenic than gp71 
alone (Hunsmann et al 1981). Using genetic engineering, all or parts of 
these proteins can be synthesized by bacteria or yeast, or chemically 
produced as small i~nunogenic polypeptides containing pertinent antigenic 
epitopes (Lerner, 1983; Nunberg et al., 1984). 
There is some previous experience with retrovirus subunit vaccines. 
Hunsmann and coworkers (1975, 1981) have inm~nized mice against Friend 
marine leukemia virus using purified viral envelope proteins gp71 or gp85 
complexes. A similar preparation, FeLV-gp85, has been used to immunize 
cats against Snyder-Theilen fibrosarcoma virus (ST-FeSV) induced tumors 
(Hunsmann et al., 1983). Feline leukemia virus-gp85 was immunogenic in 
cats, and inm~mized cats developed smaller tumors than non-vaccinated 
animals. No data was presented, however, on the retroviremia that 
accompanied tumor growth. Salerno and associates (1978), failed to induce 
neutralizing antibodies in cats with a dose of purified FeLV-gp70 that 
produced good neutralizing antibody titers in guinea pigs. The efficacy of 
this vaccine against virulent FeLV challenge exposure was not tested, 
however. 
It is essential for the success of genetically engineered subunit FeLV 
vaccines to first determine whether native viral subunits are imaunogenic 
in themselves, and more importantly, whether cats immunized with native 
viral subunit proteins are protected against virulent FeLV challenge 
exposure. It was for these reasons that the following experiments were 
conducted. In these experiments cats were immunized with inmLmoaffinity 
colunn purified FeLV-gp70 or chemically purified FeLV-gp85 and then 
challenged in various ways with virulent FeLV or FeSV. As controls for 
these studies, cats were either left unimmunized, or were vaccinated with 
formalin inactivated purified whole FeLV. Formalin inactivated whole FeLV 
vaccines have previously been shown by our laboratory to be effective 
irmmmogens in preventing persistent FeLV infection following natural 
exposure (Pedersen et al., 1978). Experimental studies reported herein 
indicated that infection with virulent FeLV may have been actually enhanced 
by preimmunization with FeLV-gp70 or -gp85 vaccines in challenge-exposure 
situations where inactivated whole FeLV vaccines were protective. 
MATERIALS ASD I~"I~ICDS 
ExPerimental animals 
Kittens 9 to 14 weeks of age were obtained from the specific pathogen 
free and conventional FeLV free breeding colonies of the Feline Leukemia 
Research Laboratory, University of California, Davis. Animals were housed 
in isolation facilities of the Animal Resources Services, University of 
California, Davis. 
Virus strains. 
The Kawakami-Theilen strain of FeLV was produced by cultures of FL74 
feline ly~phoblastoid oells (Theilen et al., 1969). This strain is in 
actuality a mixture of subgroup A, B, and C viruses (Sarma et al., 1973). 
The Snyder-Theilen strain of FeLV (ST-FeLV) was isolated from a cat that 
remained retroviremic after having recovered from a tumor induced by the 
ST-feline sarcoma virus (ST-FeSV) (Pedersen et al., 1984). Buffy ooat 
oells from the blood of this cat were cocultivated with primary fibrcblasts 
cells and the resulting infected culture was designated FF280/ST-FeLV. 
ST-FeLV is the naturally occurring helper virus present in ST-FeSV stocks 
and belongs to the interference subgroup B (Sarma et al., 1973). The 
ST-FeLV isolate is nontransforming to normal feline fibroblasts and does 
not induce fibrosarcomas. The CT600 strain of FeLV (CT600-FeLV) was a 
naturally occurring subgroup A retrovirus isolated from a leopard cat that 
lived in the same household as FeLV infected domestic cats (Rasheed et al., 
1981). The virus is replicated in a chronic fashion by CT600 leopard cat 
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testicle cells. The Rickard strain of FeLV (R-FeLV) (Rickard et al., 1969) 
was originally obtained as a cell-free tumor homogenate from Dr. Richard 
Olsen, Ohio State University. This isolate has been classified as subgroup 
A (Sarma et al, 1973). 
Preparation of inactivated whole virus v_accine. 
Cultures of FF280/ ST-FeLV cells were grown to confluency in 500 ml 
plastic flasks. Initial culture media was Eagle's minimum essential media 
(Earle's base) supplemented with an equal part of Leibowitz's-15 (LI5) 
media and 10% fetal bovine serum. After the cells reached a confluent 
state the original media was replaced with Eagle's ~ containing no fetal 
bovine serum but supplemented with 1 ug/ml of hydrocortisone phosphate. 
Tissue culture media was collected 48 hours later and concentrated 50 to 
200 fold in a millipore Pellicon apparatus with 100,000 dalton exclusion 
filters. Formalin was then added to the concentrate at a final concentra- 
tion of 0.8% formaldehyde and allowed to react for 24 hours at 4 C. Each 1 
ml of the final vaccine contained about 0.15 to 0.6 mg of ST-FeLV. 
Vaccines (0.5 ml) were adjuvanted with Freund's incomplete adjuvant (0.6 
ml), alhydrogel (0.2 ml), alhydrogel (0.2 ml) and Quil-A (15 ug) (9), or 
ethylene malic anhydride (0.3%). 
FeLV-gp70, -P27 and -PI5E assays 
All three of these FeLV structural proteins were quantitiated by a 
double sandwich type enzyme linked inmlznosorhent assay (ELISA). The assay 
procedure for FeLV-p27 was identical to that described by Lutz and co- 
workers (1983). Similar assays were used for the quantitation of FeLV 
-gp70 and -pl5E. The FeLV-gp70 assay utilized polyclonal goat anti-FeLV 
-gp70 ~og lobu l in  (NIH 815-210) for the "catcher" and monoclonal mouse 
anti-FeLV-gp70 (25-5D) IgG conjugated to horse radish peroxidase (HPASE) 
for the second antibody. The ELISA for FeLV-pI5E utilized monoclonal mouse 
anti FeLV-pI5E (29-2C) IgG as the "catcher" and monoclonal mouse anti-FeLV 
-plSE (29-22) IgG conjugated to HPASE as the second antibody. The IgG 
fraction was purified from serum or ascites fluid by the procedure of Bruck 
and coworkers (1982). These assay procedures were used to follow FeLV-gp70 
through various steps in purification to assure its separation from 
FeLV-p27 and -pI5E. The FeLV-p27 assay was also used to detect virus in the 
blood of FeLV infected cats (Lutz et al., 1983). 
Purification of FeLV-gp70 
FeLV-gp70 was prepared from KT-FeLV, ST-FeLV, and CT600-FeLV using 
Lmmunoaffinity ~olumn chromatography. Virus containing cell culture 
supernatants were clarified of particulate debris by low speed centri- 
fugation and then concentrated 40 fold on a Milipore Pellicon apparatus. 
Virus was pelleted at 18,000 rpm's for 120 min. in a Beckman Type 21 rotor 
(Beckman Instruments, Palo Alto, CA). Pelleted virus was resuspended in a 
small amount of TEN buffer (0.1 M tris, 0.001 M edta, 0.i M NaCI, pH 7.2), 
and then placed over a 10-50% continuous sucrose gradient and centrifuged 
at 25,000 rpm for 4 hr in a Beckman SW27 rotor. Gradient fractions were 
collected and assayed for FeLV-gp70 by ELISA; fractions oontaining the 
largest anounts of this protein were saved (Fig i). 
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FIGURE 1 - Continuous i0 to 50% sucrose gradient purification of FeLV 
pelleted from concentrated and clarified tissue culture media. FeLV-gp70 
protein, as determined by an ELISA assay, was concentrated near the 1.16 
g/ml region of the gradient and corresponded with the area where whole 
virions banded. 
Virus was removed from sucrose by diluting gradient fractions I:I0 with TEN 
buffer and reultracentrifugation. Pellets were resuspended in TEN buffer 
containing 0.1% Triton. Triton disrupted virus was then passed over an 
inmlmoaffinity colLmm. Immunoaffinity columns were made according to the 
procedure of Cuatrecases (1971) using cyanogen bromide activated sepharose- 
4B and mouse monoclonal IgG against 3 different epitopes of FeLV-gp70 
(monoclonal antibodies 25-5D, I-3B, and I-3C). Nonbinding proteins were 
washed through the coltmms with large volumes of TEN buffer until the 
eluting material was free of FeLV-p27 (Fig. 2). 
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FI(~/RE 2 - Immunoaffinity column purification of FeLV-gp70. The column was 
made of sepharose 4B covalently linked to anti-FeLV-gp70 mouse monoclonal 
IgG. The starting material on the column was detergent disrupted whole 
FeLV. FeLV-p27 appeared in the colunm wash-through, and when the wash 
buffer was free of this protein, the 3M KSCN gradient was started. 
FeLV-gp70 eluted between 1 and 2M KSCN. 
FeLV-gp70 was then eluted with a continuous gradient of 0 to 3M sodium 
thiocyanate in 50 mM borate buffer, pH 8.5. The resulting eluate fractions 
were then assayed for FeLV-gpT0 and fractions containing the greatest 
amounts of this material were pooled (Fig. 2). The FeLV-gpT0 rich eluate 
was then desalted on a Sephadex G25 column equilibrated with 50 ram ammonium 
bicarbonate buffer, pH 8.5. 
Purification of FeLV-gp85 
~settes made up of covalently linked FeLV envelope proteins gp70 and 
pl5E were produced from KT-FeLV by the procedure described by B/nsmann and 
coworkers (1983), and Schneider and associates (1980). Rosettes were 
assayed by SDS-PAQ~, and a major protein band was demonstrated by Coomassie 
blue stain at 85,000 daltons. When rosettes were run on reducing gels 
(Laemmli, 1970), the 85,000 dalton protein was reduced to a 70,000 (gp70) 
and 15,000/ 17,500 (pl5E) dalton protein. 
Antibody assay procedures 
Serum antibodies to whole FeLV and FeLV-gp70 were measured by an ELISA 
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procedure in 96 well microtiter plates (Imulon I, Dynatech Laboratories, 
Inc., Alexandria, VA). Wells were coated for 3 hr at 37 C with either 250 
ng of gradient purified 5% sodium dodecylsulphate disrupted FeLV, 25 ng of 
inm~inoaffinity co l~ purified FeLV-gp70, or 25 ng of purified FeLV-gp85, 
in 0.1M Na2CO3coating buffer, pH 9.6. Serum to be tested was diluted 1:200 
(whole FeLV) or 1:8 (FeLV-gpT0 or -gp85) in tris-edta saline buffer with 
0.05% tween 20 and 0.1% bovine serum albumin, pH 7.4. Diluted serum was 
incubated in the antigen coated wells for 1 hr at 37 C. After washing, a 
1:500 dilution of rabbit anti-cat IgG horse radish peroxidase conjugate 
(Cappel Laboratories, Cochranville, PA) was allowed to react for 45 min. 
Wells were then washed and the enzymatic reactions carried out with ABTS. 
Color reactions were read on a Dynatech microELISA reader (Dynatech Labora- 
tories, Inc., Alexandria, VA). Optical density readings were standard- 
ized to a known positive and negative serum included in each test run. 
Virus neutralizing antibodies were measured by an infectivity 
inhibition assay. Subconfluent monolayers of Crandell feline kidney (Crfk) 
cells were established in 96 well microtiter plates. One hundred tissue 
culture infectious doses 100% (i00 TCIDI00) of KT- or CT600-FeLV in 
0.05 ml of tissue culture media was incubated for 1 hr at 37 C with an 
equal volume of a serial two-fold dilution of the test cat serum starting 
at I:i0. Specific pathogen free cat serum was used as a negative control 
and goat anti-FeLV serum as a positive control. After incubation the 
serum-virus mixture was overlayered onto the Crfk cell monolayers and then 
incubated for 24 hours. At this time the media was completely changed. 
Tissue culture supernatants were harvested on day 7 and assayed for 
FeLV-p27 antigen. The titer of virus neutralizing antibody in a given 
serum was scored as the reciprocal of the highest dilution of serum that 
completely suppressed the expression of FeLV-p27. 
The i~unogenecity of purified FeLV-gp70 and -gp85 was tested by ELISA. 
Ninety-six well Imulon I plates were coated with 25 ng of FeLV-gp70 or 50 
ng of FeLV-gp85 per well for 3 hours at 37 C and overnight at 4 C. The 
antigens were reacted with n~use monoclonal FeLV-gp70 antibodies (1:50 
ascites fluid in 100 ul buffer) or goat anti-FeLV-gp70 serum (NIH 81S-210) 
(1:400 in 100 ul buffer) at 37 C for 1 hour. Seven different mouse mono- 
clonal antibodies and a polyclonal goat antiserum were used for this 
study, each of which neutralized various subgroups of FeLV at titers of 
1:250 or greater. Second antibodies consisted of goat anti-mouse 
IgG-HPASE (1:400), or rabbit anti-goat IgG-I~PASE (1:400) (Cappel Labora- 
tories, Cochranville, PA). Incubation was for 1 hour at 37 C. The ASTS 
substrate was allowed to react for 10 min. at ro(~ temperature. Optical 
denisty readings were scored as follows: 0.06 to 0.1 (+_), 0.i to 0.2 
(+), 0.2 to 0.3 (++), 0.3 to 0.4 (+++), greater than 0.4 (::~¢). 
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Virus challenge systems 
Two different basic challenge systems were used to test the efficacy of 
the various vaccine preparations. In the first system, cats were inocu- 
lated subcutaneously between the shoulder blades with 5 x 106 FF64, 
90/ST-FeSV cells. This cell line was a primary feline fibroblast culture 
that had been productively transformed with ST-FeSV (Pedersen et al., 
1984). Fibrosarcomas appeared at the site of inoculation within 6 days, 
concurrently with a systemic retrovirus infection. The systemic retro- 
viremia has been shown to be due almost exclusively to the FeLV helper 
virus present in ST-FeSV transformed cells (deNoronha et al., 1983; 
Pedersen et al., 1984). Vaccine protection in this system is measured by 3 
criteria, i) reduction of maximum tumor size (Hunsmann et al., 1983), 2) a 
decrease in the proportion of cats that developed progressively growing and 
fatal fibrosarcomas, and 3) a decrease in the proportion of infected cats 
that developed a persistent FeLV helper viremia during the course of tumor 
growth or after tumor regression (Pedersen et al., 1984). 
In the second challenge system, cats were inoculated oronasally with 
40,000 focus forming units (ffu's) of CT600-FeLV every other day for 8 
days, or similarly with 400,000 ffu's of R-FeLV. The CT600-FeLV was 
propagated in leopard cat testicle cells (Rasheed et al., 1981), and R-FeLV 
was propagated in fc9 feline fibroblast. Virus was titrated by the focus 
formation procedure of Fischinger and associates (1974). In this system, 
vaccine protection was measured by a decrease in the proportion of cats 
that were still viremic 12 to 16 weeks post challenge (Pedersen et al., 
1977). Retroviremia was measured weekly using an ELISA procedure for the 
detection of FeLV-p27 (Lutz et al., 1983). 
Statistical Methods 
The effect of vaccines on the post challenge-exposure incidence of 
persistent viremia was evaluated using relative odds ratios (R=ad/bc, where 
a= no. vaccinated cats developiong persistent viremia, b= no. of vaccinated 
cats with nondetectable or transient viremia, c=- no. of nonvaccinated cats 
developing persistent viremia, and d= no. of nonvaccinated cats with 
nondetectable or transient viremia). Groups of cats receiving the same or 
equivalent treatments were combined (a= a I + a 2 ........ , b= bl+b 2 ........ , 
etc. ). R-values of 1.0 indicated that the vaccines had no effect on the 
observed incidence of persistent viremia. A R-value <i indicated that the 
vaccine had an inhibitory effect on persistent viremia, while values >i 
indicated enhancement of persistent viremia. The statistical significance 
of the odds ratios were confirmed with the chi-square (X 2) test 
(Glantz, 1981). With 1 degree of freedom, a X 2 of 3.84 or greater was 
considered to be significant at the 95% confidence level (P_< 0.05). 
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~SULTS 
Analysis of purified FeLV-qD70 and -qp85 
FeLV-gp70 and -gp85 were analyzed for purity by inm~noblotting acording 
to the procedure of Towbin and associates (1979), except that the enzymatic 
reaction was developed using 0.5 mg/ml of 3,3-diaminobenzidine tetrahydro- 
chloride monohydrate (Aldrich Chemicals, Milwaukee, WI) and 0.01% hydrogen 
peroxide in 0.i M tris saline buffer, pH 7.4. A single band at a molecular 
weight of 70,000 daltons was identified in both preparations using the 
25-5D mouse monoclonal FeLV-gp70 antibody (Fig. 3). FeLV-p27 was absent 
from both preparations, while only the FeLV-gp85 contained a 17,500 dalton 
band that reacted with the mouse monoclonal FeLV-pI5E antibodies. 
I 
Figure 3 - Irmnunoblots of PA(~ purified FeLV-gp85, detergent disrupted 
whole FeLV, FeLV-gpT0, and FeLV-p27. Mouse monoclonal antibodies were 
against FeLV-gpT0, -p27, and -pl5E. FeLV-gp85, when run under reducing 
conditions, demonstrated a major band with the FeLV-gpT0 monoclonal 
antibody at 70,000 daltons and a major band with the FeLV-plSE monoclonal 
antibody at 17,500 daltons. Irmm/ncblots of whole FeLV, when reacted with 
the anti-FeLV-gpT0, -p27, and-pl5E monoclonal reagents, demonstrated 
corresponding bands of reactivity at 70,000, 27,000 and 17,500 dalton 
regions respectively. FeLV-gp70 preparations were found to react only with 
FeLV-qpT0 monoclonal antibody, and were free of FeLV-p27 and -plSE. As a 
specificity control, FeLV-p27 was also tested by immunoblotting. FeLV-p27 
was only detected by the corresponding FeLV-p27 monoclonal antibody. 
FeLV-gp70 and -gp85 were subjected to a number of physical and chemical 
insults during their purification. It was important, therefore, to deter- 
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mine whether major antigenic epitopes were still intact. The major anti- 
genic epitope of FeLV-gpT0 has been described by Nunberg and coworkers 
(1984). This epitope was contained in a 14 amino acid region in the 
amino-terminal half of -gp70, and was recognized by the 25-5D monoclonal 
antibody. To determine whether this epitope was still intact, the purified 
FeLV-gpT0 and -gp85 were used as competitors for the binding of the pero- 
xidase labeled 25-5D monoclonal antibody to whole FeLV in an ELISA assay. 
Detergent disrupted whole FeLV, FeLV-gpT0, and FeLV-gp85 all competed with 
the labeled monoclonal antibody for binding to the whole FeLV (Fig. 4). 
The purified FeLV-gp70 and -gp85 were also reacted in an ELISA against a 
battery of 7 different mouse monoclonal FeLV-gp70 antibodies and a goat 
polyclonal anti-FeLV-gpT0 serum (Table I). Purified FeLV-gp70 and -gp85 
both reacted with each of these antibodies. 
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Figure 4 - Inhibition of bindin~ of in ELISA the 25-5D mouse monoclonal 
FeLV-gp70 antibody-HPASE to purlfied FeLV by detergent disrupted whole 
FeLV, FeLV-gp70 and FeLV-gp85. Disrupted whole virus and the subunit 
proteins equally inhibited the binding of the labeled monoclonal antibody, 
indicating that the major virus neutralizing epitope was still intact in 
those preparations. 
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TABLE I 
The reactivity of purified FeLV-gp70 and-gp85 in ELISA with 
7 different virus neutralizing mouse monoclonal FeLV-gp70 
antibodies and with polyclonal goat anti-FeLV-gp70 serum 
(NIH 81S-210). 
.... Coating Antigen . 
Antibody FeLV-gp8_ 5 FeLV-gp70 
MC 18-1B + + 
MC 18-1D +++ +++ 
MC 18-2A + i l 
MC 18-2B ++ ++ 
MC 25-4C + +++ 
MC 25-5D + ++ 
MC 46-2F + ++ 
goat anti-FeLV-gp70 +++ ~" : 
Efficacy of whole FeSv vaccines 
A total of 96 kittens were vaccinated with inactivated whole FeLV 
vaccine and 87 kittens served as unvaccinated controls. These kittens were 
divided among 9 experimental groups (Tables II, III). The amount of virus 
contained in each dose of vaccine varied from 50 to 200 ml equivalents 
(approximately 150 to 600 ug/dose). Vaccinations were given at 3 week 
intervals starting when the kittens were 8 to 12 weeks of age and the total 
number of vaccinations per kitten varied from 2 to 3. Kittens were 
challenged subcutaneously with ST-FeSV (tumor cells) or oronasally with 
either R-FeLV or CT600-FeLV (tissue culture fluid) 1 week after the last 
vaccinat ion. 
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Serum antibodies to whole FeLV and FeLV-gp70 were detected by ELISA in 
almost all of the vaccinated cats (Fig. 5). Virus neutralizing antibodies, 
however, were not detected following immmization in the serum of any 
vaccinated or unvaccinated animal (data not shown). 
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FIGURE 5 - ELISA antibody titers in the serum of cats vaccinated with 
inactivated whole FeLV vaccine. The antibody responses of this group of 
animals was considered representative of the responses seen in the group as 
a whole. The upper graph depicts serum antibody levels against purified 
FeLV-gp70, while the lower graph depicts the antibody levels against whole 
detergent disrupted FeLV. Control cats did not develop appreciable ELISA 
antibody titers and were therefore not included. 
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Cats immunized with inactivated whole ST-FeLV vaccine, regardless of 
the experimental group, resisted virulent virus challenge to a greater 
degree than the control nonimmunized animals (Table II). In the case of 
the 124 kittens challenged with ST-FeSV (Table If), vaccinated cats deve- 
loped smaller tumors, fewer progressively growing tumors (6/66 vs 26/58), 
and a significantly lower incidence of persistent retroviremia (6/66 vs 
27/58, R =- 0.1, X 2= 18.8, P<0.01) than nonvaccinates. Similarly, 
ST-FeLV vaccinated cats challenged oronasally with virulent FeLV (R-FeLV or 
CT600- FeLV) developed a significantly lower rate of persistent 
retroviremia than nonvaccinated controls (1/30 vs 8/29, R=- 0.i, X 2= 
4.96, P<0.05) (Table III). 
TABLE III 
Results of experiments with inactivated whole FeLV vaccines and FeLV 
challenge exposure. 
Group vaccine adjuvant dos~.s challenge 
V46 a saline EMA 3 R-FeLV 
b 50 ml eq EMA 3 R-FeLV 
ST-FeLV 
Outcgme of Challenge 
undetectable 
or transient persistent 
y~remia viremia 
12/14 2/12 
11/12 1/12 
V50 a saline FICA 2 CT600-FeLV 4/7 3/7 
b 200 ml eq FICA 2 CT600-FeLV 8/8 0/8 
ST-FeLV 
v51 a saline EMA 2 CT600-FeLV 7/10 3/10 
b 100mgeq ~4A 2 CT600-FeLV 10/10 0/10 
ST-FeLV 
Although vaccinated cats fared far better than nonvaccinated cats as a 
group, kittens immunized with i00 to 200 ml equivalents of virus (300 to 
600 ug/dose), and challenged with either FeLV or FeSV, were significantly 
more protected against persistent viremia than kittens given 50 ml equi- 
valents (150 ug/dose) (1/49 vs 5/32) (Table IV). This indicated that 300 
to 600 ug dose was at the upper part of the linear portion of the dose 
response curve. 
T~RT F. IV 
Efficacy of different whole inactivated FeLV vaccines 
Vaccine 
Inactivated whole FeLV 
Controls 
Vaccinates 
50 ml eq 
i00 to 200 ml eq 
total (50 to 200 ml eg) 
Persistent viremia 
35/87 = 40% 
5/32 = 16% 
2/64 = 2% 
7/96 = 7% 
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Efficacy of FeLV-gp70 or -qp85 subunit vaccines 
Forty i0 to 12 week-old kittens were vaccinated with purified FeLV 
envelope proteins (Table V, VI). Subunit proteins were either derived from 
KT-FeLV (933,34,42), CT600-FeLV (V50), or ST-FeLV (V49). Challenge strains 
were either homologous in regards to the strains of virus from which the 
envelope proteins were derived (933, 34, 42), or autologous (V49, 50). The 
subunit FeLV proteins were all given in saline or Freund's incomplete 
adjuvant in 2 to 4 doses ranging from .005 to 1.0 mg per dose. 
Thirty-seven kittens served as nonvaccinated controls. 
Cats immunized with various FeLV envelope proteins produced good serum 
antibodies against whole FeLV and FeLV-gp70 (or FeLV-gp85) as detected by 
ELISA (Figs. 6,7). Virus neutralizing antibodies were not detected, 
however, in the serum of any of the vaccinated cats (data not shown). 
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FIGURE 6 - ELISA antibody titers in the serum of cats vaccinated with 
immunoaffinity column purified FeLV-gp70. The antibody response of this 
group of animals was considered representative of the responses seen in the 
group as a whole. The upper graph depicts serum antibody levels against 
purified FeLV-gp70, while the lower graph depicts the antibody levels 
against whole detergent disrupted FeLV. Control cats did not develop 
appreciable ELISA antibody titers and were therefore not included. 
Two weeks after completing their courses of immunization, subunit 
vacciD~ted cats and control animals were challenged with either FeLV or 
FeSV. Following inoculation with FeSV, both vaccinates and nonvaccinates 
developed fibrosareomas at the site of inoculation (Table IV). The mean 
peak tumor size was always smaller in cats vaccinated with FeLV-gp70 or 
-gp85. Surprisingly, the proportion of cats that remained persistently 
FeLV-helper viremic following FeSV inoculation did not mirror the decreased 
tumor growth. Vaccinates remained persistently retroviremic following 
challenge-exposure at a higher rate than oontrol animals (8/20 vs 2/22, R =- 
6.7, X 2= 3.94, p= <0.05) (Table V). Twenty FeLV -gp70 and -gp85 
vaccinated and 15 nonvaccinated kittens were challenged oronasally with 
virulent FeLV (Table VI). Following challenge-exposure, a greater propor- 
tion of vaccinated cats became persistently viremic as compared to non- 
vaccinates (13/20 vs 7/15, R=- 2.1, X 2= 0.55, p> 0.5), although the 
difference by chi-square was not statistically significant. 
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FIGURE 7 - ELISA antibody titers in the serum of cats vaccinated with 
purified FeLV-gp85 rosettes. The antibody response of this group of 
animals was representative of the responses seen in the entire group. The 
upper graph depicts the antibody levels against purified FeLV-gp85, while 
the lower graph depicts the antibody titers against detergent disrupted 
whole FeLV. Nonvaccinated control cats did not develop appreciable 
antibody titers and were therefore not included. 
142 
Overall, enhancement of persistent retroviremia by vaccination with 
purified FeLV envelope proteins was seen in 6/8 experimental groups 
(V33e,d; V42c,e; V49b; V50b). This was in contrast to the ii groups of 
cats that were vaccinated with inactivated whole FeLV vaccines, all of 
which showed a lower incidence of persistent viremia than nonvaccinates 
within the same experiments. 
DISCUSSION 
Salerno and associates (1978) concluded that purified FeLV-gp70 was 
poorly immunogenic in cats because it induced antibodies detectable by 
radioi~aunoassay but little or no virus neutralizing or cytotoxic anti- 
bodies. Our experiments confirmed their findings; none of the cats that 
we immunized with either FeLV-gpT0 or -gp85 developed virus neutralizing 
antibodies, but serum antibodies detectable by ELISA were produced against 
both whole FeLV and FeLV-gp70. 
The most surprising finding in our study was that cats vaccinated with 
FeLV-gp70 or -gp85 appeared to be more susceptible to infection with 
virulent FeLV or FeSV than nonvaccinated animals. This enhancement of 
infection was seen in 6/8 vaccine groups and was apparent whether cats were 
immunized with gpT0 or with gp85. It also occurred regardless of whether 
the challenge viruses were autologous or homologous to the strain of FeLV 
from which the purified envelope proteins were extracted. These findings 
were opposed, therefore, to the immunoprotective effect of viral envelope 
protein vaccines demonstrated for murine leukemia virus infection (HunEm~nn 
et al., 1975, 1981), bovine leukemia virus infection of sheep (Onuma et 
al., 1984), and foot-and-mouth disease of cattle (Bittle et al., 1982). 
The enhancing rather than protective effect of FeLV-gpT0, -gp85, vac- 
cines could have been due to several mechanisms. First, it was possible 
that the procedures used to purify the proteins altered their antigenicity 
in such a way that neutralizing epitopes were no longer present. This 
seemed unlikely, however, because purified FeLV-gpT0 and -gp85 competed 
equally well with whole FeLV for binding to the 25-5D mouse monoclonal 
FeLV-gp70 antibody. This antibody recognizes the major neutralizing 
epitopes of the FeLV envelope protein (Nunberg et al., 1984). In addition, 
purified FeLV-gp70 and -gp85 were immunoreactive in ELISA with 7 other 
virus neutralizing mouse monoclonal antibodies to FeLV-gp70 and with a 
highly specific goat polyclonal FeLV neutralizing antibody~ 
A second explanation for the possible enhancing effects of purified 
envelope protein vaccines was that they failed to induce the spectrum of 
inmlanity essential for protection, i.e., neutralizing antibodies as well as 
cellular im~snity. Neutralizing antibodies might be generated only as a 
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result of exposure to larger envelope polyproteins (pre-cleavage products) 
present in inmature particles and on the cell membrane. The role of 
cellular immunity in FeLV infection is largely unknown. Passive transfer 
of immune sera will greatly inhibit the retroviremia that follows exper- 
imental infection in cats (deNorohna et al., 1980), suggesting that humoral 
immunity is in~ortant in clearance of virus from the blood. Feline leu- 
kemia virus persists in the body as a latent infection, however, even in 
the face of strong humoral immunity (Pedersen, et al., 1984). Cellular 
i~manity has been implicated in the ultimate clearance of such latent 
infections in other virus systems, and such i~nunity is hard to evoke with 
killed or subunit proteins. 
As a third explanation, non-neutralizing antibodies to the envelope 
proteins might have either interfered with immunity or had an enhancing 
effect on virus infectivity and spread. Non-neutralizing antibodies might 
have bound to virus and sterically blocked the binding of virus neutrali- 
zing antibodies that were induced as a result of virulent virus challenge- 
exposure (Massey and Schochetman, 1981). Non-neutralizing antibodies may 
have acted as opsonins and enhanced the uptake of antibody coated virus by 
phagocytic cells. FeLV replicates initially in phagocytic cells in lymph 
nodes regional to the site of entry and spreads from these organs to other 
target tissues via blood borne mononuclear cells (Rojko et al., 1978). 
Because FeLV grows very well in mononuclear cells, and mononuclear cells 
migrate throughout the body, increased virus uptake by phagocytic cells 
could lead to both increased virus infectivity and dissemination. This 
scheme is not without precedence. Dengue virus infection of man can be 
enhanced by pre-existing humoral immunity to homologous serotypes of dengue 
virus or related flavivirus infections (Porterfield, 1982). In a similar 
manner, feline infectious peritonitis (FIP) virus infection can also be 
potentiated by pre-existing homologous coronavirus antibodies (Pedersen et 
al., 1980). Vaccination against FIP virus also makes the experimentally 
induced disease worse rather than better (Pedersen et al., 1983). 
A final possibility is that the envelope proteins acted as immunosup- 
presents rather than i.munogens. FeLV-pI5E has reportedly caused inmuno- 
suppression both in vitro and in vivo (Mathes et al., 1979). Cats that we 
immunized with FeLV-gp85 received both gp70 and plSE, and the plSE moiety 
may have enhanced the infectivity of the virulent FeLV challenge by virtue 
of its immunosuppressive effect. In support of this, it has been shown 
previously that FeLV-plSE, when given along with an FeLV vaccine, rendered 
cats more susoeptible to FeSV challenge than if they had received the 
vaccine alone (Mathes et al., 1979). This phenomena does not, however, 
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explain our findings, because cats immunized with FeLV-gp70 were as 
hypersensitive to infection as cats immmized with FeLV-gp85. 
The obvious question raised by these findings is whether i~mmity to 
FeLV can be induced with FeLV-gp70 or -gp85 vaccines. If the current 
findings and those of Salerno and associates (Salerno et al., 1978) are 
universally applicable, then the answer seems to be no. It is possible, 
however, that FeLV-gp70 or -gp85 would induce protective immunity if given 
in some other form, at some other dose, or with other adjuvants. These 
possibilities cannot be answered without a great deal of additional 
research. The point that should not be overlooked, however, is that many 
researchers have placed great hopes on subunit vaccines produced by 
genetically engineered bacteria or yeast, or on synthetic oligopeptides. 
These findings indicate that many problems and uncertainties exist with 
this approach, and that conventional inactivated whole virus vaccines 
should not be necessarily bypassed for the sake of more modern techniques. 
Although our FeLV-gp70 and -gp85 vaccines enhanced persistent retro- 
viremia, they did significantly reduce the growth rate of retrovirus 
induced fibrosarcomas. Why anti-FeLV-gp70 or -gp85 inm~nity would protect 
against tumors yet enhance retroviremia is not immediately understandable. 
It is known, however, that fibrosarcoma and retrovirus inm~nity are 
distinctly different phenomena (deNoronha et al., 1983; Pedersen et al., 
1984). A dichotomy between tumor and antivirus immunity in FeLV-gp70 or 
-gp85 vaccinated cats is not, therefore, incompatible with what is known 
about FeSV immunity. 
Although the current outlook for cheap and effective FeLV vaccines of 
recombinant or synthetic origin is somewhat clouded, it must be noted that 
conventional formalin inactivated whole virus vaccines worked very well. 
l%djuvanted and inactivated whole virus vaccines at a dose of 200 ml eq 
decreased the post-infection persistent viremia rate from 40 to 2% in our 
studies. This is c(mparable to the results of an earlier trial with a 
similar dose of antigen and natural contact challenge exposure (Pedersen et 
al., 1978) . 
The fact that whole inactivated FeLV is both immtmogenic and induces 
protective immmity, while FeLV-gp70 and -gp85 are only immunogenic, 
indicates either that other proteins of the virus are responsible for 
protective immunity or that the envelope proteins are more favorably 
arrayed as immunogens on whole virus than as suspensions of pure protein. 
The results of a previous study indicated that antibody to proteins in 
addition to FeLV-gp70 were also correlated with protection (Lutz et al., 
1982), thus supporting the first premise. In support of the latter 
possibility, FeLV virons are known to incorporate small amounts of me~rane 
proteins as they bud off of infected cells (Azocar et al., 1980). These 
host proteins may enhance the immunogenecity of the viral proteins. 
Another possiblity was that the dose of FeLV-gp70 or -gp85 used in these 
studies was lower than that present in 0.6 mg of whole FeLV. If about 13% 
of the viral proteins in whole FeLV was gp70, than 0.6 mg of whole virus 
would contain about 80 ug of gp70. We used 200 to 1000 mg of FeLV-gp70 or 
-gp85 per dose of vaccine in most of our experiments. It does not seem, 
therefore, that the difference in efficacy between whole virus and subunit 
protein vaccines was due to differences in the relative amounts of envelope 
protein in each. 
Experiments that seemed at firsthand to he contradictory to our own 
were recently reported by Osterhaus and coworkers (1985). They were able 
to induce low levels of virus neutralizing antibodies in 6/8 young cats 
immunized with 3 doses of ~ost imu la t ing  complexes (iscoms) containing 
FeLV-gp70-85. Moreover, these cats seemed to be much more resistant to 
experimentally induced FeLV infection than nonvaccinated control animals. 
Even the authors, however, were careful not to ascribe the protective 
effect of the vaccine solely to its envelope protein content. Their iscoms 
were made from disrupted whole virus and they induced antibodies to a wide 
range of envelope and nonenvelope proteins. In effect, the studies of 
Osterhaus and associates (1985) reconfirmed our studies with whole virus 
vaccines. To prove that envelope proteins alone were responsible for the 
protective immunity demonstrated by iscom preparations, cats should be 
vaccinated with iscoms containing envelope proteins alone. If such pre- 
parations should prove as protective as iscoms made from whole virus, then 
we will have to concede that our experiences with envelope protein vaccines 
were jaded by the adjuvants that we used. 
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